Literature DB >> 22056920

Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.

Dedee F Murrell1, Benjamin S Daniel, Pascal Joly, Luca Borradori, Masayuki Amagai, Takashi Hashimoto, Frédéric Caux, Branka Marinovic, Animesh A Sinha, Michael Hertl, Philippe Bernard, David Sirois, Giuseppe Cianchini, Janet A Fairley, Marcel F Jonkman, Amit G Pandya, David Rubenstein, Detlef Zillikens, Aimee S Payne, David Woodley, Giovanna Zambruno, Valeria Aoki, Carlo Pincelli, Luis Diaz, Russell P Hall, Michael Meurer, Jose M Mascaro, Enno Schmidt, Hiroshi Shimizu, John Zone, Robert Swerlick, Daniel Mimouni, Donna Culton, Jasna Lipozencic, Benjamin Bince, Sergei A Grando, Jean-Claude Bystryn, Victoria P Werth.   

Abstract

Our scientific knowledge of bullous pemphigoid (BP) has dramatically progressed in recent years. However, despite the availability of various therapeutic options for the treatment of inflammatory diseases, only a few multicenter controlled trials have helped to define effective therapies in BP. A major obstacle in sharing multicenter-based evidences for therapeutic efforts is the lack of generally accepted definitions for the clinical evaluation of patients with BP. Common terms and end points of BP are needed so that experts in the field can accurately measure and assess disease extent, activity, severity, and therapeutic response, and thus facilitate and advance clinical trials. These recommendations from the International Pemphigoid Committee represent 2 years of collaborative efforts to attain mutually acceptable common definitions for BP and proposes a disease extent score, the BP Disease Area Index. These items should assist in the development of consistent reporting of outcomes in future BP reports and studies.
Copyright © 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22056920      PMCID: PMC3883429          DOI: 10.1016/j.jaad.2011.06.032

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  10 in total

Review 1.  Interventions for bullous pemphigoid.

Authors:  Gudula Kirtschig; Philippa Middleton; Cathy Bennett; Dedee F Murrell; Fenella Wojnarowska; Nonhlanhla P Khumalo
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.

Authors:  Dedee F Murrell; Sarah Dick; A R Ahmed; Masayuki Amagai; Maria A Barnadas; Luca Borradori; Jean-Claude Bystryn; Giuseppe Cianchini; Luis Diaz; David Fivenson; Russell Hall; Karen E Harman; Takashi Hashimoto; Michael Hertl; Nico Hunzelmann; Pilar Iranzo; Pascal Joly; Marcel F Jonkman; Yasuo Kitajima; Neil J Korman; Linda K Martin; Daniel Mimouni; Amit G Pandya; Aimee S Payne; David Rubenstein; Hiroshi Shimizu; Animesh A Sinha; David Sirois; Detlef Zillikens; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2008-03-14       Impact factor: 11.527

3.  A pilot study of etanercept treatment for pemphigus vulgaris.

Authors:  David F Fiorentino; Miki S Garcia; Wingfield Rehmus; Alexa Boer Kimball
Journal:  Arch Dermatol       Date:  2011-01

4.  A comparison of oral and topical corticosteroids in patients with bullous pemphigoid.

Authors:  Pascal Joly; Jean-Claude Roujeau; Jacques Benichou; Catherine Picard; Brigitte Dreno; Emmanuel Delaporte; Loic Vaillant; Michel D'Incan; Patrice Plantin; Christophe Bedane; Paul Young; Philippe Bernard
Journal:  N Engl J Med       Date:  2002-01-31       Impact factor: 91.245

5.  [Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study].

Authors:  P Morel; J C Guillaume
Journal:  Ann Dermatol Venereol       Date:  1984       Impact factor: 0.777

Review 6.  Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus.

Authors:  Martin Pfütze; Andrea Niedermeier; Michael Hertl; Rüdiger Eming
Journal:  Eur J Dermatol       Date:  2007-02-27       Impact factor: 3.328

7.  A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study.

Authors:  Pascal Joly; Jean-Claude Roujeau; Jacques Benichou; Emmanuel Delaporte; Michel D'Incan; Brigitte Dreno; Christophe Bedane; Agnes Sparsa; Isabelle Gorin; Catherine Picard; Emmanuelle Tancrede-Bohin; Bruno Sassolas; Catherine Lok; Jean-Claude Guillaume; Marie-Sylvie Doutre; Marie-Aleth Richard; Frédéric Caux; Catherine Prost; Patrice Plantin; Olivier Chosidow; Christine Pauwels; Hervé Maillard; Philippe Saiag; Vincent Descamps; Jacqueline Chevrant-Breton; Olivier Dereure; Marie-France Hellot; Eric Esteve; Philippe Bernard
Journal:  J Invest Dermatol       Date:  2009-01-29       Impact factor: 8.551

8.  Reliability and convergent validity of two outcome instruments for pemphigus.

Authors:  Misha Rosenbach; Dedee F Murrell; Jean-Claude Bystryn; Sam Dulay; Sarah Dick; Steve Fakharzadeh; Russell Hall; Neil J Korman; Julie Lin; Joyce Okawa; Amit G Pandya; Aimee S Payne; Mathew Rose; David Rubenstein; David Woodley; Carmela Vittorio; Benjamin B Werth; Erik A Williams; Lynne Taylor; Andrea B Troxel; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2009-04-09       Impact factor: 8.551

9.  Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group.

Authors:  P Bernard; L Vaillant; B Labeille; C Bedane; B Arbeille; J P Denoeux; G Lorette; J M Bonnetblanc; C Prost
Journal:  Arch Dermatol       Date:  1995-01

10.  Nicotinamide and tetracycline therapy of bullous pemphigoid.

Authors:  D P Fivenson; D L Breneman; G B Rosen; C S Hersh; S Cardone; D Mutasim
Journal:  Arch Dermatol       Date:  1994-06
  10 in total
  60 in total

1.  Rituximab for autoimmune blistering diseases: recent studies, new insights.

Authors:  L Lunardon; A S Payne
Journal:  G Ital Dermatol Venereol       Date:  2012-06       Impact factor: 2.011

Review 2.  Intravenous immunoglobulin as clinical immune-modulating therapy.

Authors:  Laurent Gilardin; Jagadeesh Bayry; Srini V Kaveri
Journal:  CMAJ       Date:  2015-02-09       Impact factor: 8.262

Review 3.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

Review 4.  [Bullous pemphigoid: diagnosis and therapy].

Authors:  Andrea Kneisel; Michael Hertl
Journal:  Wien Med Wochenschr       Date:  2014-07-31

5.  Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.

Authors:  Khalaf Kridin; Reuven Bergman
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

6.  [Bullous pemphigoid].

Authors:  F Schulze; M Kasperkiewicz; D Zillikens; E Schmidt
Journal:  Hautarzt       Date:  2013-12       Impact factor: 0.751

7.  Diagnosis and management of pemphigus: Recommendations of an international panel of experts.

Authors:  Dedee F Murrell; Sandra Peña; Pascal Joly; Branka Marinovic; Takashi Hashimoto; Luis A Diaz; Animesh A Sinha; Aimee S Payne; Maryam Daneshpazhooh; Rüdiger Eming; Marcel F Jonkman; Daniel Mimouni; Luca Borradori; Soo-Chan Kim; Jun Yamagami; Julia S Lehman; Marwah Adly Saleh; Donna A Culton; Annette Czernik; John J Zone; David Fivenson; Hideyuki Ujiie; Katarzyna Wozniak; Ayşe Akman-Karakaş; Philippe Bernard; Neil J Korman; Frédéric Caux; Kossara Drenovska; Catherine Prost-Squarcioni; Snejina Vassileva; Ron J Feldman; Adela Rambi Cardones; Johann Bauer; Dimitrios Ioannides; Hana Jedlickova; Francis Palisson; Aikaterini Patsatsi; Soner Uzun; Savas Yayli; Detlef Zillikens; Masayuki Amagai; Michael Hertl; Enno Schmidt; Valeria Aoki; Sergei A Grando; Hiroshi Shimizu; Sharon Baum; Guiseppe Cianchini; Claudio Feliciani; Pilar Iranzo; Jose M Mascaró; Cezary Kowalewski; Russell Hall; Richard Groves; Karen E Harman; M Peter Marinkovich; Emanual Maverakis; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2018-02-10       Impact factor: 11.527

8.  Treatment of Bullous Pemphigoid in People Aged 80 Years and Older: A Systematic Review of the Literature.

Authors:  Meital Oren-Shabtai; Noa Kremer; Moshe Lapidoth; Eran Sharon; Lihi Atzmony; Adi Nosrati; Emmilia Hodak; Daniel Mimouni; Assi Levi
Journal:  Drugs Aging       Date:  2020-11-24       Impact factor: 3.923

9.  Demographics and Autoantibody Profiles of Pemphigoid Patients with Underlying Neurologic Diseases.

Authors:  Kelly N Messingham; Adam D Miller; Nandakumar S Narayanan; Samuel J Connell; Janet A Fairley
Journal:  J Invest Dermatol       Date:  2019-03-12       Impact factor: 8.551

10.  Association of Transient Palmoplantar Keratoderma With Clinical and Immunologic Characteristics of Bullous Pemphigoid.

Authors:  Claire Duretz; Frank Antonicelli; Céline Muller; Nina Antonicelli; Julie Plee; Manuelle Viguier; Philippe Bernard
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.